Boehringer Ingelheim’s BI 690517 shows up to 39.5% albuminuria reduction in Phase II trial
Boehringer Ingelheim has revealed promising results from its 14-week Phase II trial for BI 690517, a novel selective aldosterone synthase inhibitor. The data highlights a substantial up to 39.5% reduction in albuminuria when BI 690517 is used in conjunction with empagliflozin, an established SGLT2 inhibitor, compared to a placebo. This study represents the first of […]